Skip to content
UK

Charles Waddell

Partner

020 3319 3700

Charles.Waddell@keystonelaw.co.uk

“Very, very good and has a familiarity with the [life sciences] sector which meant we could dispense with the niceties and get down to business.”

- Chambers 2024

Charles is a highly experienced corporate finance lawyer with extensive experience in advising biotech, medtech, tech and pharma clients on equity financings, IPOs, mergers, and other corporate transactions.

Charles has acted for a wide range of clients, including startups and university spinouts on seed financings, early-stage companies on Series A rounds, biotech companies on IPOs and secondary financings, venture capital funds investing in unlisted biotech companies, pharma companies taking strategic stakes in unlisted biotech companies, selling shareholders in biotech and medtech companies on private M&A transactions, and public company takeovers of biotech and medtech companies.

Charles regularly mentors companies participating in the Biotech Industry Association Pulse Programme and KQ Labs Accelerator Programme.

Expertise

Charles advises healthcare and life sciences clients, biotech, pharma, and medical technology firms, on equity and CLN financings, IPOs, mergers and acquisitions, and joint ventures.

Experience

  • Advised F2G on multiple venture capital financings, including its $70m Series H round.
  • Advised the shareholders of Oxgene, on the sale of the company to WuXi AppTec.
  • Advised AIM listed LiDCO on its takeover by Masimo Corporation.
  • Advised AIM listed 4D Pharma on various secondary offerings and its merger with Longevity Acquisition Corporation.
  • Advised various biotech and medtech companies on convertible loan financings from the Future Fund.
  • Advised AIM listed Abzena on its IPO, various secondary financings and takeover.
  • Advised AIM listed TheraCryf on its IPO and various secondary financings.
  • Advised AIM listed Oncimmune on venture debt and equity financings.
  • Advised Puridify on a Series A round and its subsequent acquisition by GE Healthcare.
  • Advised the shareholders of Brabant Pharma on its acquisition by Zogenix.

Please note: The experience list above may include examples of work completed prior to joining Keystone Law.

Recognition

Recognised by The Legal 500 for Life Sciences 2022–2024

Recognised by Chambers UK  for Life Sciences 2024

Charles qualified as a solicitor in 1988. Prior to joining Keystone Law in 2024, he worked at the following firms:

  • Pinsent Masons
  • Fasken Martineau
  • CMS Cameron McKenna